Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. Issue 1 (January 2020)

• Record Type: Journal Article
• Authors: Wu, Tsung-Hsien; Shen, Yuan-Chi; Lee, Wei-Chia; Wang, Hung-Jen; Chuang, Yao-Chi
• Is Part Of: Journal of the Chinese Medical Association. Volume 83:Issue 1(2020)
• Publication Date: 2020-01
• Subjects: Erectile function -- Mirabegron -- Overactive bladder; Medicine -- Periodicals; 610.5
• DOI: 10.1097/JCMA.0000000000000208
• Languages: English
• ISSNs: 1726-4901

Abstract

Abstract : Background: To evaluate the change of erectile function (EF) in sexually active male overactive bladder (OAB) patients treated with Mirabegron. Mirabegron, a selective β3 adrenoceptor agonist, approved for the treatment of OAB, has been reported to relax human and rat corpus cavernosum and might have beneficial effect on EF. Methods: A total of 128 consecutive men with lower urinary tract symptoms attended urology outpatient clinic were evaluated for OAB and EF. Thirty-four sexually active OAB patients were prospectively enrolled in this study and received mirabegron 50 mg oral once a day. The evaluation of EF and OAB was based on a self-administered questionnaire containing International Index of Erectile Function (IIEF-5) and OAB symptom score (OABSS), respectively. Men with an OABSS urgency score of ≥2 and sum score of ≥3 were considered to have OAB. The therapeutic outcomes were assessed at baseline, 4, and 12 weeks. Results: Mirabegron usage was associated with a statistically significant improvement of OAB symptoms (OABSS 32.1% decrease) at 4-week follow-up and the therapeutic effects were maintained at 12-week follow-up. Mirabegron usage did not improve EF (IIEF-5 4.9% decrease at 4-week; p = 0.106, and 9.1% decrease at 12-week follow-up; p = 0.077). However, the IIEF-5 was significantly decreased in the higher baseline IIEF-5 (≥17) group (11.7% decrease; p = 0.044), noncoronary artery disease (13.2%; p = 0.007), or non-DM group (13.9% decrease; p = 0.021) at 12-week follow-up. Conclusion: This preliminary study demonstrates that mirabegron treatment of men with OAB improved OAB symptoms, but has no beneficial effect on EF.